Research: CKD progressionTehran University of Medical Sciences · Iranian Tissue Bank Research &preparation CenterIran · Tehrān
Article: Comparison of serum Neutrophil Gelatinase associated Lipocalin (NGAL) with serum creatinine in prediction of kidney recovery after renal transplantationInternational journal of Organ Transplantation. 01/2012; 3(4):176-82.
Ahmadpoor Pedram, Mahdavi-Mazdeh Mitra, Nafar Mohsen, Pour-Reza-Gholi Fatemeh, Samadian Fariba, Parvin MahmoodIranian Journal of Kidney Diseases. 01/2010;
Article: International evaluation of unrecognizably uglifying human faces in late and severe secondary hyperparathyroidism in chronic kidney disease. Sagliker syndrome. A unique catastrophic entity, cytogenetic studies for chromosomal abnormalities, calcium-sensing receptor gene and GNAS1 mutations. Striking and promising missense mutations on the GNAS1 gene exons 1, 4, 10, 4.Ismail Yildiz, Yahya Sagliker, Osman Demirhan, Erdal Tunc, Nihal Inandiklioglu, Deniz Tasdemir, Vidya Acharya, Ling Zhang, Ovidia Golea, Alaa Sabry, [......], Siddik Momin Adam, Idris Emir, Faith Ocal, Erol Usta, Necati Kiralp, Cemal Sagliker, Piril Sagliker Ozkaynak, Hasan Sabit Sagliker, Mahmoud Bassuoni, Oktay Sekin[show abstract] [hide abstract]
ABSTRACT: Hypotheses explaining pathogenesis of secondary hyperparathyroidism (SH) in late and severe CKD as a unique entity called Sagliker syndrome (SS) are still unclear. This international study contains 60 patients from Turkey, India, Malaysia, China, Romania, Egypt, Tunisia, Taiwan, Mexico, Algeria, Poland, Russia, and Iran. We examined patients and first degree relatives for cytogenetic chromosomal abnormalities, calcium sensing receptor (Ca SR) genes in exons 2 and 3 abnormalities and GNAS1 genes mutations in exons 1, 4, 5, 7, 10, 13. Our syndrome could be a new syndrome in between SH, CKD, and hereditary bone dystrophies. We could not find chromosomal abnormalities in cytogenetics and on Ca SR gene exons 2 and 3. Interestingly, we did find promising missense mutations on the GNAS1 gene exons 1, 4, 10, 4. We finally thought that those catastrophic bone diseases were severe SH and its late treatments due to monetary deficiencies and iatrogenic mistreatments not started as early as possible. This was a sine qua non humanity task. Those brand new striking GNAS1 genes missense mutations have to be considered from now on for the genesis of SS.Journal of Renal Nutrition 01/2012; 22(1):157-61. · 1.57 Impact Factor
Article: Establishing the Global Kidney Disease Prevention Network (KDPN): a position statement from the National Kidney Foundation.[show abstract] [hide abstract]
ABSTRACT: The Global Kidney Disease Prevention Network is an international public health organization devoted to encouraging and enhancing efforts to increase awareness and recognition of kidney disease, detect it early, and provide treatment to prevent disease progression, improve patient outcomes, and decrease costs. Twenty-six participants from 12 low-, middle-, and high-income countries attended the first meeting, held in Geneva, Switzerland, on September 12-13, 2009. Work groups discussed target populations for chronic kidney disease (CKD) screening, optimal parameters for screening on a public health level, evaluating the impact of early screening programs, and use of screening data to inform health care policy. Of the screening programs discussed, most have targeted populations at high risk of CKD and have included medical history; weight, height, and blood pressure measurements; and blood and urine tests. In screenees, CKD prevalence ranged from 11%-33%. In screenees with CKD, few were aware of the disease, although substantial proportions had been seen by a physician in the previous 6-12 months. At the policy level, prevention of CKD implies prevention and control of risk-factor conditions, including diabetes, hypertension, and others. Given the high prevalence and under-recognition of CKD in different countries, a concerted effort to globally improve primary and secondary CKD prevention appears to be warranted.American Journal of Kidney Diseases 03/2011; 57(3):361-70. · 5.43 Impact Factor